In the quest for improved recovery times following anterior cruciate ligament (ACL) reconstructions, the University of Cincinnati College of Medicine is poised to spearhead a pivotal national study. Researchers plan to investigate the extended use of tranexamic acid (TXA), a cost-effective drug commonly used during surgery to reduce bleeding. This new trial, which is set to commence patient enrollment in early 2026, could potentially revolutionize recovery protocols for young athletes who suffer from ACL injuries.
According to a University of Cincinnati News release, the study will home in on the effects of administering TXA after surgery - a departure from its typical use. "In this study, we're administering this to patients outside of the operating room in the first week after ACL surgery to try to limit how much bleeding they have in the knee, how much swelling, (and) therefore how much pain they have," David Bernholt, MD, detailed in an interview with 91.7 WVXU News. The focus is on accelerating the recovery process by improving early increases in motion through the reduction of post-operative pain and swelling.
Taking the helm of the investigation is Dr. Bernholt, an associate professor of clinical medicine in the Department of Orthopaedic Surgery's Division of Sports Medicine at the university. The clinical trial will span over five national sites and aims to enroll 100 participants between the ages of 14 and 22. Simple in structure, the randomized study will split the participants into two groups: one receiving the TXA orally for seven days post-surgery, and the other receiving a placebo. Over the span of a year, the recovery of these individuals will be meticulously tracked and analyzed.
Previous research into the administration of TXA following full knee replacement surgery has shown promising early results regarding alleviation of pain and improvement in joint mobility. "Even if that's all researchers find, it would still be a win," Dr. Bernholt asserted to 91.7 WVXU News. He pinpoints the significant potential for this study to amend national medical practices, explaining that "If we see in the group that gets the medication that they are at a higher percentage ready to return to sport at nine months, versus the group that does not, that's what will make this practice changing across the country," according to UC News. Moreover, the significance of these findings will not be limited to the professional realm but will also deeply resonate with young athletes whose sports careers are on the line.
The implications of this study are not just medical but have a considerable impact on the lives and futures of young athletes. In certain cases, a reduction in recovery times could drastically alter the trajectory of a high school athlete's career. For an athlete who sustains an ACL injury, a recovery time shortened by several months could mean the difference between missing an entire year of play or making it back in time for the next season. In sports, timing is everything, and for these young competitors, losing two seasons due to an extended recovery could be nothing short of devastating.
